Literature DB >> 635475

Group A meningococcal polysaccharide vaccine and course of the group A meningococcal epidemic in Finland.

H Peltola.   

Abstract

A group A meningococcal epidemic started in Finland in 1973 and had its peak in 1974. Its rapid decline and end after large scale vaccinations in 1975-76, involving approximately one quarter of the population, is described. It gives further proof of the clinical efficacy of the group A polysaccharide vaccine. No corresponding increase in the other serogroups has been seen in the 1 1/2 years elapsed after these vaccinations.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 635475     DOI: 10.3109/inf.1978.10.issue-1.09

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  13 in total

1.  Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: meeting at the crossroads.

Authors:  Dace V Madore; Bruce D Meade; Fran Rubin; Carolyn Deal; Freyja Lynn
Journal:  Vaccine       Date:  2010-05-12       Impact factor: 3.641

2.  Different seroprevalences of antibodies against Neisseria meningitidis serogroup A and Haemophilus influenzae type b in Sudanese and Swedish children.

Authors:  M A Salih; H Fredlund; S Hugosson; L Bodin; P Olcén
Journal:  Epidemiol Infect       Date:  1993-04       Impact factor: 2.451

3.  Epidemic group C meningococcal meningitis in Upper Volta, 1979.

Authors:  C V Broome; M A Rugh; A A Yada; L Giat; H Giat; J M Zeltner; W R Sanborn; D W Fraser
Journal:  Bull World Health Organ       Date:  1983       Impact factor: 9.408

4.  Comparison of passive hemagglutination, bactericidal activity, and radioimmunological methods in measuring antibody responses to Neisseria meningitidis group A capsular polysaccharide vaccine.

Authors:  H Käyhty
Journal:  J Clin Microbiol       Date:  1980-08       Impact factor: 5.948

5.  Physical heterogeneity of neisserial lipooligosaccharides reflects oligosaccharides that differ in apparent molecular weight, chemical composition, and antigenic expression.

Authors:  J M Griffiss; J P O'Brien; R Yamasaki; G D Williams; P A Rice; H Schneider
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

6.  Targeted vaccination with meningococcal polysaccharide vaccine in one district of the Czech Republic.

Authors:  P Kriz; J Vlckova; M Bobak
Journal:  Epidemiol Infect       Date:  1995-12       Impact factor: 2.451

7.  Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia.

Authors:  Hani Jokhdar; Ray Borrow; Abdulrazaq Sultan; Mousaed Adi; Christine Riley; Emily Fuller; David Baxter
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

8.  Recognition of serogroup A Neisseria meningitidis serotype antigens by human antisera.

Authors:  R J Sugasawara
Journal:  Infect Immun       Date:  1985-04       Impact factor: 3.441

9.  Electromorphic characterization and description of conserved epitopes of the lipooligosaccharides of group A Neisseria meningitidis.

Authors:  J J Kim; R E Mandrell; Z Hu; M A Westerink; J T Poolman; J M Griffiss
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

10.  Meningococcal disease in Scandinavia.

Authors:  H Peltola; K Jónsdóttir; A Lystad; C J Sievers; I Kallings
Journal:  Br Med J (Clin Res Ed)       Date:  1982-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.